🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

10 recruiting trials

for Metastatic Renal Cell Carcinoma (mRCC)

Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients NCT05817903Phase 223 sites📍 Brescia📍 Candiolo📍 Catania Consorzio Oncotech · Tests: Axitinib, Nivolumab Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer NCT07128680Phase 12 sites📍 Duarte📍 Irvine City of Hope Medical Center · Tests: Biospecimen Collection, Bone Scan, Computed Tomography, Faecalibacterium prausnitzii-containing Bacterial Strain Formul… Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer NCT07227415Phase 1, Phase 2183 sites📍 Phoenix📍 Scottsdale📍 Fayetteville Pfizer · Tests: PF-08634404, Ipilimumab, Axitinib, Casdatifan PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk NCT07175480Phase 21 site📍 Nanjing Jinling Hospital, China · Tests: Intermittent PD-1/PD-L1 ICI + VEGFR-TKI TDM for Optimized Outcome in Patients With mRCC. NCT04659343n/a1 site📍 Aarhus Niels Fristrup · Tests: Measurement of concentration of active metabolite in cancer treatment. Urine Omics Predicting IO Therapy Responses in mRCC Patients NCT04712305n/a1 site📍 Taipei National Taiwan University Hospital · Tests: No intervention required Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer NCT06601296Phase 21 site📍 Dallas University of Texas Southwestern Medical Center · Tests: IMSA101 Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma NCT05287945Phase 1, Phase 210 sites📍 Orange📍 Palo Alto📍 San Francisco Oncorena AB · Tests: Orellanine International Multicentric Study ARON-1 NCT05287464n/a1 site📍 Province of Macerata Hospital of Macerata · Tests: pembrolizumab plus axitinib A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) NCT07188896Phase 25 sites📍 Washington D.C.📍 Chapel Hill📍 Hershey Brian Rini · Tests: Fianlimab, Ipilimumab, Nivolumab, Cemiplimab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy